Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medicure Inc. (V:MPH)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 1250 Waverley Street
WINNIPEG MB R3T 6C6
Tel: N/A
Website: https://www.medicure.com
IR: See website
Key People
Albert D. Friesen
Chairman of the Board, Chief Executive Officer
Neil Owens
President, Chief Operating Officer
Haaris Uddin
Chief Financial Officer
Business Overview
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Financial Overview
For the nine months ended 30 September 2023, Medicure Inc revenues decreased 1% to C$16.6M. Net income applicable to common stockholders decreased 31% to C$627K. Revenues reflect Marketing & Distribution of Commercial Products segment decrease of 15% to C$9.5M. Net income also reflects Selling/General/Admin Expense increase of 22% to C$5.4M (expense), Change in fair value of contingent consi decrease from C$302K (income) to C$0K.
Employees: 25 as of Dec 31, 2022
Reporting Currency: Canadian Dollars
Enterprise value: $8.52M as of Sep 30, 2023
Annual revenue (TTM): $22.94M as of Sep 30, 2023
EBITDA (TTM): $3.33M as of Sep 30, 2023
Net annual income (TTM): $1.08M as of Sep 30, 2023
Free cash flow (TTM): $1.47M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 10,436,313 as of Sep 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization